𝔖 Bobbio Scriptorium
✦   LIBER   ✦

L-683,877: Pharmacological profile of a novel 5-HT3 receptor antagonist

✍ Scribed by Dr. David Tattersall; Nigel Newberry; Margaret S. Beer; Mike Rigby; Michael Gilbert; Janet J. Maguire; Nikki Mudunkotuwa; Mark Duchnowski; Alexander T. McKnight; Christopher J. Swain; Clare Kneen; Colin T. Dourish

Publisher
John Wiley and Sons
Year
1992
Tongue
English
Weight
731 KB
Volume
25
Category
Article
ISSN
0272-4391

No coin nor oath required. For personal study only.

πŸ“œ SIMILAR VOLUMES

Zatosetron, a selective 5-HT3 receptor a
Zatosetron, a selective 5-HT3 receptor antagonist: Pharmacological activities of human and animal metabolites
✍ Marlene L. Cohen; William Bloomquist; Christopher R. Schmid; David W. Robertson; πŸ“‚ Article πŸ“… 1993 πŸ› John Wiley and Sons 🌐 English βš– 555 KB

## Abstract Zatosetron is a potent, orally active 5‐HT~3~ receptor antagonist with a long duration of activity in laboratory animals and humans. Several metabolites have been detected in plasma and urine of humans and experimental animals receiving zatosetron. The present study was designed to expl

Neurochemical profile in vitro of irinda
Neurochemical profile in vitro of irindalone: A5-HT2-receptor antagonist
✍ John Hyttel; Klaus BΓΈGesΓΈ; Hanne LΓΈVe LembΓΈL; Jens-JΓΈRgen Larsen; Eddi Meier πŸ“‚ Article πŸ“… 1988 πŸ› John Wiley and Sons 🌐 English βš– 866 KB

A new potential antihypertensive drug, irindalone (Lu 21 -098;( +)-(1 R,3S)-1-[2-[4-[3-(pf luoropheny1)-1 -indanyl]-1 -piperazinyl]ethyl]-2-imidazolidinone), has been characterized by a series of in vitro methods. lrindalone competitively inhibits peripheral and central serotonin;! (5-HT2) receptors